VTC方案加入非转移性尤文肉瘤初始治疗:III期随机试验
这项III期随机试验比较标准五药间期压缩化疗(A组)与在其中加入VTC(B组)治疗初治非转移性尤文肉瘤,共642例入组、309例接受标准治疗、320例接受实验治疗。VTC未改善生存,但该结果代表目前初治非转移性尤文肉瘤的最佳生存估计。
要点
- 在标准五药间期压缩化疗中加入VTC未改善无事件生存或总生存。
- 肿瘤体积≥200 mL与较低无事件生存显著相关。
核心结论
- 在五药间期压缩化疗中加入VTC未改善初治非转移性尤文肉瘤患者的生存。
- 本试验结果代表目前该人群的最佳生存估计。
研究设计与样本
- III期随机试验,入组642例初治非转移性尤文肉瘤患者,309例接受标准五药间期压缩化疗17周期(A组),320例接受含5周期VTC的17周期实验治疗(B组)。
- 按诊断年龄(<18岁和≥18岁)和肿瘤部位(骨盆骨、非骨盆骨和骨外)分层,诊断时肿瘤体积分类为<200 mL或≥200 mL,局部控制在6周期后实施。
主要发现
- 5年EFS和OS分别为78%和87%。
- 骨盆、非骨盆骨和骨外原发肿瘤患者的5年EFS分别为75%、78%和85%。
- 肿瘤体积≥200 mL与较低EFS显著相关。
临床怎么用
- 对于初治非转移性尤文肉瘤,标准五药间期压缩化疗仍是合理选择,加入VTC未显示生存获益。
- 年龄≥18岁和肿瘤体积≥200 mL提示预后较差,可用于风险分层和咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed chemotherapy improved survival outcomes for patients with previously untreated nonmetastatic Ewing sarcoma. METHODS: Patients were randomly assigned to receive standard five-drug interval compressed chemotherapy (regimen A) for 17 cycles or experimental therapy with five cycles of VTC within the 17 cycles (regimen B). Patients were stratified by age at diagnosis (< 18 years and ≥18 years) and tumor site (pelvic bone, nonpelvic bone, and extraosseous). Tumor volume at diagnosis was categorized as < 200 mL or ≥ 200 mL. Local control occurred following six cycles. Histologic response was categorized as no viable or any viable tumor. Event-free survival (EFS) and overall survival (OS) were compared between randomized groups with stratified log-rank tests. RESULTS: Of 642 enrolled patients, 309 eligible patients received standard and 320 received experimental therapy. The 5-year EFS and OS were 78% and 87%, respectively. There was no difference in survival outcomes between randomized groups (5-year EFS regimen A v regimen B, 78% v 79%; P = .192; 5-year OS 86% v 88%; P = .159). Age and primary site did not affect the risk of an EFS event. However, age ≥ 18 years was associated with an increased risk of death at 5 years (hazard ratio 1.84; 95% CI, 1.15 to 2.96; P = .009). The 5-year EFS rates for patients with pelvic, nonpelvic bone, and extraosseous primary tumors were 75%, 78%, and 85%, respectively. Tumor volume ≥ 200 mL was significantly associated with lower EFS. CONCLUSION: While VTC added to five-drug interval compressed chemotherapy did not improve survival, these outcomes represent the best survival estimates to date for patients with previously untreated nonmetastatic Ewing sarcoma.
引用
- Leavey PJ, Laack NN, Krailo MD, et al. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021. PMID: 34652968. doi:10.1200/JCO.21.00358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。